Alcon Inc. (ALC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALC POWR Grades
- Stability is the dimension where ALC ranks best; there it ranks ahead of 93.33% of US stocks.
- ALC's strongest trending metric is Growth; it's been moving up over the last 179 days.
- ALC's current lowest rank is in the Momentum metric (where it is better than 8.48% of US stocks).
ALC Stock Summary
- With a market capitalization of $32,722,635,000, ALCON INC has a greater market value than 93.26% of US stocks.
- ALCON INC's stock had its IPO on April 9, 2019, making it an older stock than just 15.95% of US equities in our set.
- ALC's current price/earnings ratio is 71.6, which is higher than 93.57% of US stocks with positive earnings.
- Stocks with similar financial metrics, market capitalization, and price volatility to ALCON INC are CSGP, A, RMD, HOLX, and FTV.
- Visit ALC's SEC page to see the company's official filings. To visit the company's web site, go to www.alcon.com.
ALC Valuation Summary
- ALC's price/earnings ratio is 71.5; this is 232.56% higher than that of the median Healthcare stock.
- Over the past 41 months, ALC's price/sales ratio has gone down 0.2.
Below are key valuation metrics over time for ALC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ALC | 2022-09-01 | 3.8 | 1.7 | 71.5 | 61.7 |
| ALC | 2022-08-31 | 3.7 | 1.7 | 70.7 | 61.0 |
| ALC | 2022-08-30 | 3.7 | 1.7 | 70.6 | 61.0 |
| ALC | 2022-08-29 | 3.7 | 1.7 | 70.9 | 61.2 |
| ALC | 2022-08-26 | 3.8 | 1.7 | 71.8 | 61.9 |
| ALC | 2022-08-25 | 4.0 | 1.8 | 75.0 | 64.5 |
ALC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALC has a Quality Grade of C, ranking ahead of 38.86% of graded US stocks.
- ALC's asset turnover comes in at 0.284 -- ranking 134th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows ALC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.284 | 0.508 | 0.035 |
| 2021-03-31 | 0.252 | 0.448 | -0.033 |
| 2020-12-31 | 0.249 | 0.430 | -0.052 |
| 2020-09-30 | 0.248 | 0.438 | -0.075 |
| 2020-06-30 | 0.249 | 0.451 | -0.065 |
| 2020-03-31 | 0.273 | 0.489 | -0.023 |
ALC Stock Price Chart Interactive Chart >
ALC Price/Volume Stats
| Current price | $67.80 | 52-week high | $88.78 |
| Prev. close | $67.85 | 52-week low | $63.92 |
| Day low | $66.76 | Volume | 254,449 |
| Day high | $68.32 | Avg. volume | 838,668 |
| 50-day MA | $71.26 | Dividend yield | N/A |
| 200-day MA | $75.35 | Market Cap | 33.23B |
Alcon Inc. (ALC) Company Bio
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.
Latest ALC News From Around the Web
Below are the latest news stories about ALCON INC that investors may wish to consider to help them evaluate ALC as an investment opportunity.
Top 10 Stock Picks of Nicolai Tangen’s Ako CapitalThis article discusses the top 10 stock picks of Nicolai Tangen’s hedge fund Ako Capital at the end of the quarter on June 30. If you are interested in knowing only about Ako Capital’s top five picks, you can check them here: Top 5 Stock Picks of Nicolai Tangen’s Ako Capital. Nicolai Tangen’s Ako Capital, […] |
Why Aerie Pharmaceuticals Was Soaring So High This WeekYou'd vault skyward, too, if a big-pocketed company were willing to spend a lot of coin on acquiring you. |
What Does Aerie Buyout Mean for Alcon (NYSE:ALC)?Swiss eye-care company Alcon (NYSE:ALC) has signed a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for roughly $770 million. The deal, which is expected to boost Alcon’s financials, is in sync with its initiatives to expand its ophthalmic pharmaceutical offerings. Through this transaction, Aerie’s Rocklatan, Rhopressa and AR-15512 will become a part of Alcon’s portfolio. Notably, AR-15512 is currently a Phase 3 product candidate for treating dry eye disease. Further, Aerie’s pipeline of drugs, comprising multiple clinical and preclinical ophthalmic pharmaceutical product candidates, will also come under Alcon post the deal. Coming to the financial terms of the deal, Alcon is acquiring at a price of $15. |
Analysts’ Top Healthcare Picks: Alcon (ALC), Geron (GERN)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alcon (ALC – Research Report) and Geron (GERN – Research Report) with bullish sentiments. Alcon (ALC) Needham analyst David Saxon maintained a Buy rating on Alcon today and set a price target of $85.00. The company's shares closed last Tuesday at $68.83. According to TipRanks. |
Stocks Cut Lower As Dow Sheds Another Triple DigitsThough most sectors are suffering today, especially real estate and healthcare, energy stocks are on the rise as oil prices make a big resurgence. |
ALC Price Returns
| 1-mo | -10.16% |
| 3-mo | -3.23% |
| 6-mo | -7.14% |
| 1-year | -19.24% |
| 3-year | 15.70% |
| 5-year | N/A |
| YTD | -22.18% |
| 2021 | 32.04% |
| 2020 | 16.63% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...